Essex Investment Management Co. LLC acquired a new position in Edwards Lifesciences Corp (NYSE:EW) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 6,333 shares of the medical research company’s stock, valued at approximately $714,000.

A number of other hedge funds have also recently modified their holdings of EW. Dimensional Fund Advisors LP raised its stake in shares of Edwards Lifesciences by 0.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 591,853 shares of the medical research company’s stock valued at $69,977,000 after purchasing an additional 4,014 shares in the last quarter. OxFORD Asset Management LLP acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at about $708,000. Prudential PLC acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at about $238,000. Shelton Capital Management acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at about $364,000. Finally, Janus Henderson Group PLC raised its stake in shares of Edwards Lifesciences by 83.1% in the 2nd quarter. Janus Henderson Group PLC now owns 50,178 shares of the medical research company’s stock valued at $5,934,000 after purchasing an additional 22,768 shares in the last quarter. Hedge funds and other institutional investors own 81.52% of the company’s stock.

A number of equities research analysts have recently issued reports on EW shares. Cowen restated a “buy” rating and issued a $135.00 target price on shares of Edwards Lifesciences in a research note on Thursday, October 12th. Canaccord Genuity reiterated a “buy” rating and set a $135.00 price objective (down previously from $155.00) on shares of Edwards Lifesciences in a research note on Wednesday, October 25th. SunTrust Banks set a $124.00 price objective on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Barclays dropped their price objective on shares of Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 25th. Finally, Morgan Stanley dropped their price objective on shares of Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating on the stock in a research note on Thursday, October 26th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Edwards Lifesciences currently has a consensus rating of “Buy” and a consensus price target of $139.25.

In other news, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $127.24, for a total value of $674,372.00. Following the completion of the transaction, the vice president now directly owns 24,908 shares in the company, valued at $3,169,293.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Larry L. Wood sold 18,960 shares of the stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $104.76, for a total transaction of $1,986,249.60. The disclosure for this sale can be found here. Insiders sold 175,940 shares of company stock valued at $20,049,578 over the last quarter. Insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corp (NYSE EW) opened at $129.70 on Thursday. Edwards Lifesciences Corp has a 1 year low of $89.20 and a 1 year high of $138.48. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.15. The company has a market cap of $26,892.66, a PE ratio of 45.03, a price-to-earnings-growth ratio of 1.88 and a beta of 0.63.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.91 by $0.03. The business had revenue of $888.50 million during the quarter, compared to analysts’ expectations of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.69%. The business’s revenue was up 15.7% on a year-over-year basis. During the same period last year, the firm posted $0.75 earnings per share. sell-side analysts forecast that Edwards Lifesciences Corp will post 4.49 earnings per share for the current year.

Edwards Lifesciences announced that its Board of Directors has authorized a share buyback program on Thursday, December 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its stock is undervalued.

ILLEGAL ACTIVITY NOTICE: “6,333 Shares in Edwards Lifesciences Corp (EW) Purchased by Essex Investment Management Co. LLC” was first reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2018/02/08/6333-shares-in-edwards-lifesciences-corp-ew-purchased-by-essex-investment-management-co-llc.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.